At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 8 enrolled
Drug / intervention
Alemtuzumabdrug
Likely dose
Alemtuzumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
In Brief
A Phase 4 clinical trial evaluating Alemtuzumab for Multiple Sclerosis. Completed, enrolled 8 participants.
Detailed Summary
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
Countries--
CollaboratorsGenzyme, a Sanofi Company
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJul 2011
Primary CompletionOct 2015
Study CompletionJul 2017
TodayJul 2026
First PostedJul 15, 2011
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2015
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.0 years ago
Interventions
Alemtuzumabdrug
10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.